EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Talquetamab improves patient‐reported symptoms and health‐related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL‐1 study

Carolina Schinke, Cyrille Touzeau, Albert Oriol, María-Victoria Mateos, Don Stevens, Leo Rasche, Xiang Qin, Kelly Kato, Sacheeta Bathija, Eva G Katz, Katharine S Gries, Michela Campagna und 10 weitere

Cancer · 15.07.2025 · 131 (14)

DOI: 10.1002/cncr.35927 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer, online erschienen am 09.07.2025. Verfasst von Carolina Schinke und 21 weiteren Autor:innen. Beteiligte Einrichtung: Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Myeloma, Neoplasm Recurrence, Local, Quality of Life. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Talquetamab is the first approved G protein–coupled receptor family C group 5 member D–targeting bispecific antibody for the treatment of triple‐class exposed relapsed/refractory multiple myeloma (RRMM) on the basis of results from the phase 1/2 MonumenTAL‐1 study ( ClinicalTrials.gov identifiers NCT03399799 and NCT04634552). This study describes patient‐reported outcomes (PROs) among patients who received talquetamab in MonumenTAL‐1.

Methods

PROs were assessed in phase 2 of MonumenTAL‐1. Patients had RRMM with ≥3 prior lines of therapy (proteasome inhibitors, immunomodulatory drugs, and anti‐CD38 antibodies). Patients included in these analyses received talquetamab 0.8 mg/kg every other week. PRO assessments included European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30), EuroQol 5‐Dimension 5‐Level Visual Analogue Scale (EQ‐5D‐5L VAS), and Patient Global Impression of Severity (PGIS).

Results

As of January 29, 2024, PRO data were available for 118 patients who received ≥1 dose of talquetamab. Compliance for completion was >95% of patients at baseline and >80% at most posttreatment visits. After an initial worsening in most PROs from baseline through cycle 1, patients reported improvements with continued treatment. At cycle 21, least‐squares mean change from baseline showed improvements in global health status (4.9 points) and emotional functioning (12.5 points), along with reductions in pain (11.4 points) and fatigue (4.0 points). The proportion of patients with clinically meaningful improvements or no change from baseline increased throughout treatment. EQ‐5D‐5L VAS and PGIS scores demonstrated improvement in health‐related quality of life.

Conclusions

These PRO results complement the efficacy and safety profile of talquetamab, which highlights talquetamab as a viable treatment option for patients with triple‐class exposed RRMM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificMultiple MyelomaNeoplasm Recurrence, LocalQuality of LifeAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPatient Reported Outcome Measures

Stichwörter der Autor:innen

bispecific antibodyhealth‐related quality of lifemultiple myelomapatient‐reported outcome measures

Substanzen

Antibodies, Bispecifictalquetamab

Autor:innen und Institutionen

  • Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Centre Hospitalier Universitaire de Nantes, Nantes, France.
  • Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
  • Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, IBMCC-USAL, CSIC, Salamanca, Spain.
  • Norton Cancer Institute, Louisville, Kentucky, USA.
  • University Hospital of Würzburg, Würzburg, Germany.

Förderung

  • Johnson & Johnson

Zitieren

APA

Schinke, C., Touzeau, C., Oriol, A., Mateos, M. V., Stevens, D., Rasche, L., Qin, X., Kato, K., Bathija, S., Katz, E. G., Gries, K. S., Campagna, M., Masterson, T., Hilder, B. W., Tolbert, J., Renaud, T., Heuck, C., Tomlinson, C., Moreau, P., …, & Chari, A. (2025). Talquetamab improves patient‐reported symptoms and health‐related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL‐1 study. Cancer, 131(14). https://doi.org/10.1002/cncr.35927

Vancouver

Schinke C, Touzeau C, Oriol A, Mateos MV, Stevens D, Rasche L, et al. Talquetamab improves patient‐reported symptoms and health‐related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL‐1 study. Cancer. 2025;131(14). doi:10.1002/cncr.35927

BibTeX
@article{Schinke2025,
  author = {Schinke, Carolina and Touzeau, Cyrille and Oriol, Albert and Mateos, María-Victoria and Stevens, Don and Rasche, Leo and Qin, Xiang and Kato, Kelly and Bathija, Sacheeta and Katz, Eva G and Gries, Katharine S and Campagna, Michela and Masterson, Tara and Hilder, Brandi W and Tolbert, Jaszianne and Renaud, Thomas and Heuck, Christoph and Tomlinson, Chalmer and Moreau, Philippe and San-Miguel, Jesús and Rodríguez-Otero, Paula and Chari, Ajai},
  title = {Talquetamab improves patient‐reported symptoms and health‐related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL‐1 study},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {14},
  doi = {10.1002/cncr.35927}
}
Kostenlos starten →